These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21847362)

  • 1. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
    Wang YW; Tu PH; Lin KT; Lin SC; Ko JY; Jou YS
    Neoplasia; 2011 Aug; 13(8):704-15. PubMed ID: 21847362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
    Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
    J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
    Wu H; Zeng C; Ye Y; Liu J; Mu Z; Xie Y; Chen B; Nong Q; Wu D
    Mol Pharm; 2018 May; 15(5):1892-1900. PubMed ID: 29595984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS signaling in ALK fusion lung cancer.
    Hrustanovic G; Bivona TG
    Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
    Vishwamitra D; Li Y; Wilson D; Manshouri R; Curry CV; Shi B; Tang XM; Sheehan AM; Wistuba II; Shi P; Amin HM
    Am J Pathol; 2012 May; 180(5):1772-80. PubMed ID: 22414602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
    Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
    Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.